By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Emergent BioSolutions 

2273 Research Boulevard
Suite 400
Rockville  Maryland  20850  U.S.A.
Phone: 301-795-1800 Fax: 301-795-1899

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent’s development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia.

Key Statistics

Ownership: Public

Web Site: Emergent BioSolutions
Symbol: EBS

Company News
Emergent BioSolutions (EBS) Expands Biodefense Business Through Launch Of A Military-Grade Auto-Injector Device For Chemical Threats 8/3/2015 8:01:25 AM
Emergent BioSolutions (EBS) To Release Second Quarter 2015 Financial Results And Conduct A Conference Call On August 6, 2015 7/23/2015 8:19:27 AM
Emergent BioSolutions (EBS) Awarded $19.7 Million Biomedical Advanced Research and Development Authority (BARDA) Contract To Develop And Manufacture Ebola Monoclonal Antibodies 7/20/2015 7:24:55 AM
Emergent BioSolutions (EBS) Signs Long-Term Manufacturing Agreement With ProMetic Life Sciences Inc. (PFSCF.PK) 5/19/2015 8:36:45 AM
Emergent BioSolutions (EBS) To Hold Annual Meeting Of Stockholders Thursday May 21, 2015 At 9:00 AM Eastern; Webcast Will Be Available 5/14/2015 1:29:02 PM
Oxford University, GlaxoSmithKline (GSK) And Emergent BioSolutions (EBS) Announce Initiation Of A Prime Boost Study Of Ebola Vaccine Candidates 5/13/2015 7:43:05 AM
Soligenix (SNGX) Announces Development Agreement With Emergent BioSolutions (EBS) 5/13/2015 6:40:15 AM
Emergent BioSolutions (EBS) Reports First Quarter 2015 Financial Results 5/8/2015 7:54:14 AM
CMC Biologics In Commercial Supply Agreement With Emergent BioSolutions (EBS) For FDA-Approved IXINITY 5/5/2015 6:14:36 AM
Emergent BioSolutions (EBS) Expands Commercial Product Portfolio With FDA Approval Of IXINITY, A Recombinant Factor IX Treatment For Hemophilia B 4/30/2015 8:43:30 AM